Mayo Clinic, Rochester, Minnesota 55905, USA.
Am J Chin Med. 2010;38(4):695-703. doi: 10.1142/S0192415X10008160.
External qigong as a pharmacotherapy adjunct was investigated in 50 subjects with chronic pain (pain lasting > 3 months with pain score of > or = 3 on 0-10 numeric analog scale) who presented to a qigong healing center. Participants were randomized to receive either external qigong treatment (EQT) or equivalent attention time (EAT) in weekly 30-min sessions for four consecutive weeks. Outcomes were assessed before and after sessions. The primary outcome measure was intensity of pain by a 10-cm visual analog scale used to rate all pain severity measurements. At 8-week follow-up, participants were contacted by telephone and mailed a questionnaire. Most had experienced pain for > 5 years (66%); the rest, for > 3 to 5 years (8%), 1 to 3 years (10%), or < 1 year but > 3 months (10%). The most frequent concomitant diagnoses were multifactorial (26%), osteoarthritis (18%), and low back pain (12%). Most patients were also receiving other treatments (74%); none previously had EQT. Participants were randomly assigned to EQT (n = 26) or EAT (n = 24). These groups had no significant differences at baseline except for prior awareness of qigong (EQT 31% vs. EAT 63%; p = 0.025). Compared to the EAT group, EQT participants had a significant decrease in pain intensity in the 2nd (p = 0.003), 3rd (p < 0.001), and 4th weeks of treatment (p = 0.003). At week 8, these differences in overall decreased pain intensity persisted but were not statistically significant.
气功作为一种辅助药物治疗的方法,在 50 名患有慢性疼痛(疼痛持续时间 > 3 个月,疼痛评分 > = 3 分,0-10 数字模拟评分)的患者中进行了研究,这些患者前往气功治疗中心就诊。参与者被随机分配接受气功治疗(EQT)或等效关注时间(EAT),每周 30 分钟,连续四周。在治疗前后评估结果。主要结局测量指标是使用 10 厘米视觉模拟评分来评估所有疼痛严重程度的疼痛强度。在 8 周随访时,通过电话联系参与者并邮寄问卷。大多数人经历疼痛超过 5 年(66%);其余人经历疼痛超过 3 至 5 年(8%)、1 至 3 年(10%)或 < 1 年但 > 3 个月(10%)。最常见的伴随诊断是多因素(26%)、骨关节炎(18%)和下腰痛(12%)。大多数患者还接受其他治疗(74%);以前没有人接受过 EQT。参与者被随机分配到 EQT(n = 26)或 EAT(n = 24)组。除了对气功的认识(EQT 组为 31%,EAT 组为 63%;p = 0.025)外,这两组在基线时没有显著差异。与 EAT 组相比,EQT 组在第 2(p = 0.003)、3(p < 0.001)和 4 周的治疗中疼痛强度显著降低(p = 0.003)。在第 8 周,整体疼痛强度降低的这些差异仍然存在,但没有统计学意义。